Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

THE TRUTH ABOUT: Antares pharma s return on capital employed overview - The Untold Story

According to Benzinga Pro, during Q4, Antares Pharma (NASDAQ:ATRS) earned $32.68 million, a 506.03% increase from the preceding quarter. Antares Pharma also posted a total of $48.73 million in sales, a 1.12% increase since Q3. Antares Pharma earned $5.39 million, and sales totaled $48.19 million in Q3.

What Is ROCE?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.